The tyrosine kinase inhibitor Gefitinib reduces C. elegans stress-induced sleep, but not likely via LET-23/EGFR inhibition.
MicroPubl Biol
; 20242024.
Article
in En
| MEDLINE
| ID: mdl-38545437
ABSTRACT
The anticancer drug Gefitinib is a tyrosine kinase inhibitor with selectivity for the Epidermal Growth Factor Receptor (EGFR/ErbB1). As the C. elegans EGF receptor LET-23 shares notable structural homology over its kinase domain with human EGFR, we wished to examine whether Gefitinib treatment can interfere with LET-23-dependent processes. We show that Gefitinib disrupts C. elegans stress-induced sleep (SIS) but does not impact EGF overexpression-induced sleep nor vulva induction. These findings indicate that Gefitinib does not interfere with LET-23 signaling and impairs SIS through an off-target mechanism.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
MicroPubl Biol
Year:
2024
Document type:
Article
Country of publication: